Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545660 | 0.89 | L3MBTL3 (0.43) | MCHR1RORCKCNH2 | |
| SCHEMBL189270 | 0.87 | HRH3 (0.37) | MCHR1RORCKCNH2MAP4K4HRH3 | |
| SCHEMBL16719407 | 0.84 | MCHR1 (0.56) | MCHR1RORCKCNH2PIM1PIM3 | |
| SCHEMBL27752850 | 0.84 | MCHR1 (0.56) | MCHR1RORCKCNH2PIM1PIM3 | |
| SCHEMBL13174962 | 0.84 | MCHR1 (0.56) | MCHR1RORCKCNH2PIM1PIM3 | |
| SCHEMBL14924424 | 0.82 | MCHR1 (0.49) | MCHR1RORCKCNH2MAP4K4 | |
| SCHEMBL27389111 | 0.82 | MCHR1 (0.49) | MCHR1RORCKCNH2MAP4K4 | |
| SCHEMBL14450799 | 0.82 | MCHR1 (0.49) | MCHR1RORCKCNH2MAP4K4 | |
| SCHEMBL34469712 | 0.82 | MCHR1 (0.49) | MCHR1RORCKCNH2MAP4K4HRH3 | |
| SCHEMBL24681150 | 0.81 | MCHR1 (0.59) | MCHR1RORCKCNH2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101312977-B | Fused heterocyclic compounds useful as kinase modulators | BRISTOL MYERS SQUIBB CO | 2012-06-13 | — | — | CN | claimed |
| EP-2213673-B1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8329711-B2 | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| EP-2213673-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-7179832-B2 | Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE1, WEE2, CCNE1 | MCHR1 1599/4885RORC 2350/4885KCNH2 447/4885 |
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | GSK3B, GSK3A, GYS2 | MCHR1 4752/4885RORC 1299/4885KCNH2 3969/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | MCHR1 3039/4885RORC 2907/4885KCNH2 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.